Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
Authors
Keywords
-
Journal
International Journal of Environmental Research and Public Health
Volume 19, Issue 14, Pages 8577
Publisher
MDPI AG
Online
2022-07-15
DOI
10.3390/ijerph19148577
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- European cancer mortality predictions for the year 2022 with focus on ovarian cancer
- (2022) M. Dalmartello et al. ANNALS OF ONCOLOGY
- Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
- (2022) Rebecca Kristeleit et al. LANCET ONCOLOGY
- Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
- (2021) Camilla Nero et al. Cancers
- Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic
- (2021) Aruni Ghose et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry
- (2021) Nicholas Pavlidis et al. Cancer Epidemiology
- BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
- (2021) Sidrah Shah et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
- (2020) Richard T. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
- (2020) Stergios Boussios et al. Drugs in research & development
- Wise Management of Ovarian Cancer: On the Cutting Edge
- (2020) Stergios Boussios et al. Journal of Personalized Medicine
- Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?
- (2020) Michele Moschetta et al. Annals of Translational Medicine
- Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer
- (2019) Kathleen N Moore et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- Epithelial ovarian cancer risk: A review of the current genetic landscape
- (2019) Nicola Flaum et al. CLINICAL GENETICS
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
- (2019) Boussios et al. Diagnostics
- Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
- (2019) Stergios Boussios et al. Diagnostics
- Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
- (2019) Joyce F. Liu et al. GYNECOLOGIC ONCOLOGY
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural basis of homologous recombination
- (2019) Yueru Sun et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach
- (2019) Stergios Boussios et al. INVESTIGATIONAL NEW DRUGS
- Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
- (2019) Mansoor Raza Mirza et al. LANCET ONCOLOGY
- The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
- (2019) Andrew A. Davis et al. Journal for ImmunoTherapy of Cancer
- Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2 -Mutated Carcinomas
- (2018) Khyati Meghani et al. Cell Reports
- A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: Diagnostic and therapeutic perspectives
- (2018) Stergios Boussios et al. Journal of Advanced Research
- ATALANTE (ENGOT-ov29): A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.
- (2018) Jean Emmanuel Kurtz et al. JOURNAL OF CLINICAL ONCOLOGY
- 53BP1 cooperation with the REV7–shieldin complex underpins DNA structure-specific NHEJ
- (2018) Hind Ghezraoui et al. NATURE
- The shieldin complex mediates 53BP1-dependent DNA repair
- (2018) Sylvie M. Noordermeer et al. NATURE
- Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028
- (2018) Andrea Varga et al. GYNECOLOGIC ONCOLOGY
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers
- (2018) Ying L. Liu et al. Current Oncology Reports
- Ovarian carcinosarcoma: Current developments and future perspectives
- (2018) Stergios Boussios et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
- (2017) Stephanie A. Yazinski et al. GENES & DEVELOPMENT
- Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study
- (2017) E. Pujade-Lauraine et al. GYNECOLOGIC ONCOLOGY
- PARP inhibitors: Clinical utility and possibilities of overcoming resistance
- (2017) Benjamin G. Bitler et al. GYNECOLOGIC ONCOLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
- (2017) Beatrice Rondinelli et al. NATURE CELL BIOLOGY
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2017) Olga Kondrashova et al. Cancer Discovery
- The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer
- (2017) Jun Li et al. Oncotarget
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
- (2017) Joline Lim et al. Cancers
- Epidemiology of ovarian cancer: a review
- (2017) Reid Brett M. et al. Cancer Biology & Medicine
- Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germlineBRCA1/2mutation: a multistudy analysis of response rates and safety
- (2016) U. A. Matulonis et al. ANNALS OF ONCOLOGY
- Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies
- (2016) STERGIOS BOUSSIOS et al. ANTICANCER RESEARCH
- The DNA damage-induced cell death response: a roadmap to kill cancer cells
- (2016) Sonja Matt et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- PARP inhibitor combination therapy
- (2016) Amy Dréan et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- PD-L1 Expression in Lung Cancer
- (2016) Hui Yu et al. Journal of Thoracic Oncology
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial
- (2016) H. J. Gray et al. Journal for ImmunoTherapy of Cancer
- Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients
- (2015) Vasiliki Michalarea et al. CANCER RESEARCH
- Abstract CT324: Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus olaparib cohort
- (2015) Ursula A. Matulonis et al. CANCER RESEARCH
- Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
- (2015) S. Kummar et al. CLINICAL CANCER RESEARCH
- A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
- (2015) Robert L. Coleman et al. GYNECOLOGIC ONCOLOGY
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Regulators of homologous recombination repair as novel targets for cancer treatment
- (2015) Małgorzata Krajewska et al. Frontiers in Genetics
- Immunotherapeutic approaches to ovarian cancer treatment
- (2015) Cariad Chester et al. Journal for ImmunoTherapy of Cancer
- PARP inhibitors in ovarian cancer: Current status and future promise
- (2014) Joyce F. Liu et al. GYNECOLOGIC ONCOLOGY
- A Novel Murine T-Cell Receptor Targeting NY-ESO-1
- (2014) Shannon F. Rosati et al. JOURNAL OF IMMUNOTHERAPY
- Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
- (2014) Joyce F Liu et al. LANCET ONCOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
- (2012) J. Karbach et al. CLINICAL CANCER RESEARCH
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor
- (2012) Louise J Barber et al. JOURNAL OF PATHOLOGY
- Immunotherapy in ovarian cancer
- (2012) Gina M. Mantia-Smaldone et al. Human Vaccines & Immunotherapeutics
- The MRE11 complex: starting from the ends
- (2011) Travis H. Stracker et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors
- (2009) J. P. Palma et al. CLINICAL CANCER RESEARCH
- The promise and potential pitfalls of chimeric antigen receptors
- (2009) Michel Sadelain et al. CURRENT OPINION IN IMMUNOLOGY
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started